cyrilzakka/clinical-trials huggingface dataset:
A Study in Belgian Children Hospitalized With Respiratory Syncytial Virus Related Acute Respiratory Infections

The purpose of the study is to assess viral kinetics and clinical symptoms kinetics in pediatric patients hospitalized with Respiratory Syncytial Virus (RSV) confirmed lower respiratory tract infection (LRTI).

This is an exploratory prospective study (a study in which the patients are identified and then followed forward in time for the outcome of the study). The study will consist of two phases: a screening phase (Day 1) and an assessment phase (Day 2 to Day 7). During screening phase, in pediatric patients hospitalized with LRTI and from whom the informed consent form was obtained, diagnosis of RSV infection will be performed within 24h from the hospital admission, using a SOFIA POC test on nasal specimens. During the assessment phase the collection of nasal specimens will be done daily for a maximum of 6 days (Day 2 to Day 7 of hospitalization) or until patient discharge from hospital. Approximately 50 patients will be enrolled in this study. The total duration of the study for each participant will be approximately 7 days. The study duration will extend during 1-3 RSV epidemic seasons, or until the targeted number of 50 RSV hospitalized children have completed the study.

Eligibility Criteria:
Inclusion Criteria:

* Legal representative has provided Ethics Committee approved written informed consent prior to any study-related procedure(s) being performed and is willing to allow the participation of child to the study for 7 consecutive days or until hospital discharge (whatever comes first)
* Participant hospitalized with lower respiratory tract infection (LRTI) during respiratory syncytial virus (RSV) epidemics, within 24h of hospitalization. The diagnosis of LRTI will follow the standard medical procedure in the hospital unit
* Onset of acute respiratory symptoms was less than or equal to 5 days ago
* For the participation in the assessment phase the hospitalized participant will have an RSV confirmed infection based on SOFIA RSV point of care (POC) test

Exclusion Criteria:

- Participant does not fulfill the inclusion criteria
The Correlation of Intracranial Artery Calcification and Outcomes of Mechanical Thrombectomy

CAIS-MT is a single-center, prospective cohort study, to evaluate the correlation between outcomes of endovascular treatment(EVT) and intracranial artery calcification(IAC) in patients with acute ischemic stroke due to large or medium vessel occlusion.

This study have to objective to evaluate the predictive value of IAC Agatston score in patients with acute ischemic stroke due to large or medium vessel occlusion on worse angiographic and functional outcomes after EVT. The result of this study will provide a upfront basis for risk stratification of adverse outcomes of EVT by using quantitative IAC, so as to get a reference for an individualized and precise plan of EVT.

Eligibility Criteria:
Inclusion Criteria:

* Male or non-pregnant women with acute stroke symptoms aged over 18 years.
* Occlusion of the intracranial internal carotid artery, the middle cerebral artery, the anterior cerebral artery, the posterior cerebral artery, basilar artery and intracranial vertebral artery confirmed by CT, MR angiography, or digital subtraction angiography.
* No absolute contraindication to iodinated contrast media.
* Planned treatment with EVT by clinical care team.
* Informed consent obtained from patients or their legal representatives.
* Willing to be followed up as required by the clinical study protocol.

Exclusion Criteria:

* Acute ischemic stroke occurs over 24 hours of time last known well.
* Neurologic deficits caused by diagnoses other than ischemic stroke, such as intracerebral hemorrhage, subarachnoid hemorrhage, or intracranial tumors.
* With other underlying factors leading to IAC, such as hyperthyroidism, end-stage renal disease, long-term oral intake of vitamin K antagonist(Warfarin), chronic vitamin D deficiency or overdose, persistent hypomagnesemia, persistent hypercalcemia, persistent hyperphosphatemia and high oral calcium intake.
* Lack of non-contract CT images on admission and significant artifacts in CT images preventing IAC measurement.
* Severe renal insufficiency (estimated glomerular filtration rate \< 30ml/min or serum creatinine \> 220μmol/L (2.5mg/dl)).
* Previous cerebrovascular intervention treatment or craniotomy.
Brain Mechanisms of Reducing Polysubstance Use

The proposed study will test whether neurofeedback (NF) could optimize integrative body-mind training (IBMT) practice.

The proposed study will test whether real-time NF could optimize IBMT practice and improve effects in reducing polysubstance use through targeting self-control networks in the brain.

Eligibility Criteria:
Inclusion Criteria:

* At least 18 years old
* Free of any psychiatric diagnoses or medication (besides a substance use disorder (SUD) to alcohol, tobacco, or cannabis)
* In the past month, at least 4 episodes of heavy episodic drinking; at least 3 occasions of cannabis use; and daily cigarette use for at least the past month
* Normal or corrected-to-normal vision
* Written informed consent
* No previous meditation or NF experiences

Exclusion Criteria:

* Any psychiatric diagnoses other than an SUD
* Medical disorder(s) that may affect the central nervous system; medications that affect the central and autonomic nervous system; or a positive pregnancy test result (females)
* Excluding cannabis, evidence of recent (past month) illicit drug use
Impact of Videoconference Updates in Neonatal Intensive Care Unit on Parental Stress of Preterm Infants (VISIO-NEONAT)

The aim of the study is to test the effect of daily videoconference updates between parents of preterm newborns and health care providers which also offer them the possibility of seeing their child on the parental stress in a neonatal intensive care unit (NICU).


Eligibility Criteria:
Inclusion Criteria:

* Parents with a preterm child born between 24 weeks and 34 weeks and 6 days of gestational age, hospitalized in our NICU during recrutment period
* Which agreed participating to the study after having complete information about it and sign a consent.

Exclusion Criteria:

* Parents with a preterm child with another pathology than prematurity or with a lenght of stay in the NICU less than 7 days
* Parents refusing to participate to the study
* Parents not having videoconference equipment or internet access at home
* Parents not understanding or speaking good enough French.
Study on the Relationship Between Neutrophil-mediated Thrombocytopenia and the Condition and the Course of Disease in Patients With HFRS

Thrombocytopenia is an important pathological feature of HFRS（Hemorrhagic Fever With Renal Syndrome, HFRS）. However, the cause of thrombocytopenia in HFRS is not yet fully understood. Neutrophils, as the largest number of white blood cells in the human body, can widely participate in the immune process of viral infections. Previous studies have found that the neutrophils of patients with acute myocardial infarction can interact with activated platelets and further mediate platelet phagocytosis.Therefore, this study aims to systematically elucidate the immunological process of neutrophil mediated thrombocytopenia in patients with HFRS by exploring the correlation between platelet activation, neutrophil activation and neutrophil proportion of adherent / phagocytic platelets peripheral blood of HFRS patients, and to analyze its relationship with the course of HFRS disease, which lays a theoretical foundation for further understanding the pathogenesis of HFRS and provides a basis for clinical use.


Eligibility Criteria:
Inclusion Criteria:

* Age ≥18 years;
* Clinical diagnosis meets the diagnostic criteria of the national HFRS prevention and treatment plan (Hantavirus-specific IgM antibody is positive). The classification and staging standards of HFRS patients are based on the "Expert Consensus of Shaanxi Province on Diagnosis and Treatment of Hemorrhagic Fever with Renal Syndrome".

Exclusion Criteria:

* Age \<18 years;
* Have a history of kidney disease;
* Have a history of liver disease;
* Have a history of malignant tumor;
* Receive dialysis treatment before admission;
* Combined with hypertension, coronary heart disease and diabetes history;
* Combined with HIV infection and patients with autoimmune diseases and pregnancy.
Cognitive Functions in Patients With Multiple Sclerosis

Approximately 65% of multiple sclerosis (MS) patients appear to have problems in their cognitive function. Long-term memory is one of the most frequently affected functions in MS patients. Many factors play a role in the deterioration of cognitive functions because of many symptoms of MS.

The aim of this study is to investigate the relationship of cognitive function with physical factors such as balance, functional exercise capacity and personal factors such as fatigue level, mood, sleep quality in patients with MS.

Patients with MS between 0-5,5 score according to the Extended Disability Status Scale (EDSS) and healthy individuals of similar age and sex to patients will be included in the study. The cognitive function, balance, functional exercise capacity, fatigue, mood, sleep quality will be evaluated once.

Investigators will use descriptive statistics and t-tests to compare variables between groups. Investigators will examine the correlations between variables using Pearson bivariate correlations. The significance level is set at p\<0,05.

Eligibility Criteria:
Inclusion Criteria:

* Participants who 18-65 years of age
* MS patients who are ambulatory (Expanded Disability Status Scale score ≤ 5,5 ) in a stable phase of the disease, without relapses in the last 3 month.

Exclusion Criteria:

* Participants who have orthopedic, vision, hearing, or perception problems
OptiScanner Versus Standard Blood Glucose Monitoring

The study is to demonstrate the accuracy of the OptiScanner in measuring blood glucose levels in critically ill patients when compared to a reference YSI 2300 STAT Plus and the Gem 3000, the reference standard for Erasme University Hospital.


Eligibility Criteria:
Inclusion Criteria:

* Signed Informed consent.
* Age ≥ 18 years.
* Admitted to the ICU of Erasme University Hospital.
* Expected ICU stay of ≥ 3 days at the time of enrollment (as judged by the Principle Investigator).
* APACHE II score of ≥ 10, within the first 24 hours of ICU admission.
* Existing central venous catheter + arterial catheter.
* No participation in any other investigational interventional study while enrolled in this study.
* Hyperglycemia (BG \> 150 mg/dl) at the time of admission.

Exclusion Criteria:

* Pregnancy.
Modelling Internal Hepatic Movement With an External Abdominal Marker

This study tests the feasibility and reproducibility of patient-specific motion models. These will be used for quantification of safe margin reduction. Patient-specific motion models will be built by post-processing 4D MRI data with non-rigid registration. By comparing these models between visits, model reproducibility will be assessed, and the methodology refined.

The study will use a real time position management (RPM) system for respiratory gating. The RPM system senses the respiration motion of the patient by tracking a pair of reflective markers on a lightweight "marker block" constructed of a synthetic material. This block is placed on the patient's abdomen.

During Radiotherapy, the beam is only switched on at pre-determined phases of respiration. The appropriate phase of respiration is determined by the RPM system. This implies a reliable correlation of external block motion to internal hepatic movement. This correlation is not a simple one, and requires "modeling".

Eligibility Criteria:
Inclusion Criteria:

* Histologically confirmed adenocarcinoma compatible with primary disease in the colon or rectum
* Aged 18 years or older
* Unequivocal contrast-enhanced CT and/or MRI evidence of malignant single or multiple metastases in the liver, metastases at other sites will not be an exclusion criterion
* WHO performance status 0-2 and life expectancy of at least 12 weeks
* Informed written consent

Exclusion Criteria:

* Pregnancy or breast feeding
* Evidence of ascites
* Patients unable for whatever reason to lie flat
* Patients unable to give fully informed consent
* Age\< 18 years
Immediate Implant With Provisionalization

Prospective observational clinical study conducted to evaluate the success of graftless immediate implantation with provisionalizaion

In this study 35 graftless immediately placed implant in smile line loaded by provisional office made restoration, the primary and secondary stability measured and compared in addition to evaluation of pink esthetic score

Eligibility Criteria:
Inclusion Criteria:

1. Medical and psychological fitness for minor oral surgery.
2. Age 20-60 years.
3. medium to thick gingival biotype.
4. buccal plate thickness more than (1mm).

Exclusion Criteria:

1. Smoking habit.
2. Diabetes mellitus.
3. A systemic disorder that is contraindicated for the minor surgical procedure.
4. Pregnancy or lactation.
5. Any irradiation in head and neck area.
6. Need for bone augmentation procedure.
7. Clinical signs of bruxism or other severe functional disorders.
8. patient with periodontal disease.
Efficacy And Safety Of Combination Therapy For Treatment Of Overactive Bladder In Male Patients With Benign Prostatic Hyperplasia.

The purpose of this study is to investigate the safety and efficacy of combination therapy involving β3-adrenoceptor agonist, mirabegron, and α-blockers for the treatment of OAB symptoms in male patients with BPH.

Mirabegron (MyrbetriqTM, Astellas Pharma Inc.) is a drug that is approved by the FDA for the treatment of overactive bladder (OAB) with symptoms of urinary frequency, urgency and urgency incontinence. Multiple studies have shown that this drug also has the potential to improve patient tolerability, compliance and subsequent patient quality of life without inducing unfavourable adverse events commonly associated with antimuscarinic medications. These adverse events include, but are not limited to, dry mouth, constipation, confusion, and acute urinary retention (AUR).

Studies now have shown that mirabegron may also provide an effective treatment option for OAB in men with benign prostatic hyperplasia (BPH) without inducing the above mentioned adverse events. This study will look at the combination therapy of Mirabegron and Tamsulosin, versus Tamsulosin and placebo alone to prove that this treatment (Mirabegron and Tamsulosin) is effective for those men who suffer from both overactive bladder along with benign prostatic hyperplasia.

Eligibility Criteria:
Inclusion Criteria:

* Male patients over the age of 50
* Clinical BPH on stable dose of alpha-blocker therapy for more than 1 month
* OAB symptoms (frequency, urgency, nocturia, urgency incontinence)

Exclusion Criteria:

* Post-void residual (PVR) \> 200mL
* Active, culture-proven urinary tract infection
* Acute/chronic prostatitis
* Previous lower urinary tract malignancy (i.e. bladder, prostate malignancy)
* History of cystolithiasis
* Previous pelvic surgery (i.e. prostatectomy, cystectomy, recent pelvic/endourologic instrumentation including cystoscopy, nephroscopy, ureteral stent insertion, Transrectal Ultrasound (TRUS) biopsy)
* Previous pelvic radiation
Patient Preference for Radial Versus Femoral Vascular Access

The purpose of this study is to determine the preference of patients regarding the vascular access site in future coronary procedures. We hypothesize that patients prefer the lesser invasive procedure via radial access.

Rationale: To explore patient preference for vascular access site in percutaneous coronary procedures, by assessing the perceived importance of benefits and risks of both transradial access and transfemoral access. In addition, direct preference for vascular access and preference for shared decision-making were evaluated.

Objective: To investigate the patient preference of vascular access -transradial versus transfemoral- in future percutaneous coronary procedures, by use of the Best-Worst Scaling.

Study design: Single-center, prospective, observational registry

Study population: A consecutive series of patients, who between June and August 2014, underwent elective coronary procedures at Thoraxcentrum Twente in Enschede.

Intervention: All subjects will receive a questionnaire containing basic baseline questions and a best-worst scaling scenario in which they were asked to indicate the most and least desirable characteristics of the vascular access approach.

Furthermore, their direct preference was asked and to which extent they preferred to participate in the decision-making process regarding the choice for vascular access route in future percutaneous coronary procedures.

Main study endpoints:

* The primary endpoint is the patient preference on specific treatment characteristics with regard to vascular access in coronary procedures.
* Secondary endpoints include

  1. direct patient preference for transradial access or transfemoral access
  2. the valuation of participation in decision-making on the choice of vascular access together with the interventional cardiologist.

Eligibility Criteria:
Inclusion Criteria:

* All patients who undergoing an elective coronary procedure at Thoraxcenteum Twente in the period of June 2014 until August 2014

Exclusion Criteria:

* Language barrier
Botanical Tincture for Symptoms of Irritable Bowel Syndrome

The main purpose of this study is to investigate the feasibility of a follow-up larger RCT on the efficacy of Botanical Tincture to relieve abdominal pain in people with Irritable Bowel Syndrome Constipation Predominant (IBS-C).

The randomized pilot trial will address subject recruitment, retention, and subject compliance with protocol. A secondary is to learn if people with IBS-C are able to tolerate Botanical Tincture and the effect of taking Botanical Tincture on abdominal pain, bloating, and bowel movements.

Eligibility Criteria:
Inclusion Criteria:

* Patients meeting ROME IV criteria for the diagnosis of irritable bowel syndrome that requires that patients have had recurrent abdominal pain on average at least 1 day per week during the previous 3 months that is associated with 2 or more of the following :
* Related to defecation (may be increased or unchanged by defecation)
* Associated with a change in stool frequency
* Associated with a change in stool form or appearance
* Abdominal Pain Intensity: average of worst daily (in past 24 hours) abdominal pain score of \>= 3 on a 0 to 10 point scale over last week
* Stool Frequency: \< or = to 3 Complete Spontaneous Bowel Movement(CSBM) in the previous week
* Reported bloating rating \> or = 2 on 5-point scale \[0 (absent) - 4 (very severe)\] in previous week
* English speakers, as all surveys are in English

Exclusion Criteria:

* Patients with known hypersensitivity to any component of the trial drugs
* History of eating disorders
* Patients with a history of diseases with abdominal symptoms that can resemble IBS
* Presence of any other known acute or chronic gastrointestinal disorder
* History of abdominal surgery (cholecystectomy and appendectomy can be tolerated when performed at least one year previously)
* Pregnancy or breast feeding
* Current or past history of alcohol dependence
* Based on lack of adequate scientific evidence to predict drug-drug interaction in vivo, current use of strong inhibitors or inducers for CYP enzymes and participants are instructed not to take any medications that are strong inhibitors or inducers for CYP enzymes during the course of the study
* Vulnerable Subjects. The study will not include vulnerable subjects (such as, those with limited autonomy or those in subordinate hierarchical positions). Children, pregnant women, nursing home residents or other institutionalized persons, students, employees, fetuses, prisoners, and persons with decisional incapacity will not be included.
The Effect of COVID-19 on Diabetes Mellitus

The study aimed to evaluate the effect of SARS-COV-2 infection on metabolic status in patients with diabetes mellitus. Patients' HbA1c levels before and after SARS-COV-2 infection will be evaluated.

In this time pediods, all patients with RT-PCR positive for SARS-COV-2 will be analysed for the presence of diabetes mellitus. Previous HbA1c levels will be obtained from hospital records. In these patients, previous A1c levels and A1c levels 3 months after the SARS-COV-2 infection will be compared.

Eligibility Criteria:
Inclusion Criteria:

- All hospitalised diabetic patients with RT-PCR- positive for SARS-COV-2 will be enrolled.

Exclusion Criteria:

- The absence of diabetes mellitus RT-PCR- negative for SARS-COV-2 Non-hospitalised patients
Sucralfate to Improve Oral Intake in Children With Infectious Oral Ulcers: a Randomized, Double-blind, Placebo-Controlled Trial

The purpose of this study is to see if sucralfate, a medication commonly used for patients with stomach ulcers, may help pediatric patients with mouth ulcers decrease their pain level and improve their ability to drink.


Eligibility Criteria:
Inclusion Criteria:

* Age ≥6 months and ≤5 years old
* Present with oral infectious ulcers such as gingivostomatitis, herpangina, or hand, foot and mouth disease
* History of decreased oral fluid intake by parent or guardian
* English or Spanish speaking parents or guardians

Exclusion Criteria:

* Severely dehydrated or toxic, requiring immediate resuscitation
* Exclusively breastfed
* Severe dental disease
* Significant mouth trauma
* Active Malignancy
* Preexisting upper airway obstruction or swallowing difficulties
* Received intravenous fluids within 24 hours
* Administration of BOTH acetaminophen AND ibuprofen prior to triage and within 4 hours of enrollment
Multispectral Imaging to Characterize Patterns of Vascular Supply Within Lymphoepithelial Mucosa in Oropharyngeal Cancer

The purpose of this study is to characterize the blood supply at the base of the tongue and within the tonsil region. We hypothesize that high-resolution Narrow Band Imaging (NBI) will improve the diagnosis of oropharyngeal carcinoma (OPC). The goal is to provide the better assessment of tumor and thus providing better preoperative expectations to patients with OPC or tumor extent prior to radiation therapy.


Eligibility Criteria:
Inclusion Criteria:

* age 18 years or older
* Written informed consent
* Patients with oropharyngeal carcinoma

Exclusion Criteria:

* Tumors of the oral cavity or nasopharynx